Healthcare / Medical DistributionThailand
$0.87
+0.00 (+0.00%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 22%
FCF escenarios
weak_data · normalized FCF $-55.2M · quality 61.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
34/100
D
Piotroski
2/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$348M
P/E
14.5x
↓EV/EBITDA
7.9x
↓ROE
2.4%
↑Gross Margin
42.7%
↓Debt/Equity
0.57
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-2.7%
FCF CAGR
—
FCF margin
-7.7%
FCF / Net income
-3.30x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $647.0M · net income $15.2M · FCF $-50.0M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $647.0M | $647.0M | $654.4M | $639.2M | $703.4M |
| Net Income | $15.2M | $15.2M | $29.3M | $30.6M | $60.7M |
| EBITDA | $87.6M | $87.6M | $96.2M | $89.2M | $117.2M |
| EPS | — | — | 0.07 | 0.08 | 0.15 |
| Gross Margin | 42.7% | 42.7% | 40.8% | 40.4% | 37.2% |
| Operating Margin | 1.3% | 1.3% | 3.7% | 5.3% | 8.3% |
| Net Margin | 2.3% | 2.3% | 4.5% | 4.8% | 8.6% |
| Balance Sheet | |||||
| Debt/Equity | 0.57 | 0.57 | 0.49 | 0.42 | 0.29 |
| Current Ratio | 1.75 | 1.75 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-50.0M | $-50.0M | $-83.8M | $-55.2M | $-140.5M |
| Returns | |||||
| ROE | 2.4% | 2.4% | 4.6% | 5.1% | 10.2% |
| Valuation | |||||
| P/E | 14.50 | 14.50 | 45.75 | 43.38 | 28.53 |
| EV/EBITDA | 7.89 | 7.89 | 16.85 | 17.46 | 15.46 |
| P/B | 0.55 | 0.55 | 2.11 | 2.21 | 2.88 |
| Growth & Yield | |||||
| Revenue Growth | -1.1% | -1.1% | 2.4% | -9.1% | — |
| EPS Growth | — | — | -5.2% | -48.7% | — |
| Dividend Yield | 2.0% | 2.0% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-60.9%
Start / end P/E
n/dx → n/dx
EPS bridge
0.07 → n/d
Residual
-62.9%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.